TransMedics Group WKN: A2PH5P ISIN: US89377M1099 Kürzel: TMDX Forum: Aktien Thema: Hauptdiskussion

Net income for the third quarter of 2024 was $4.2 million, or 3.9% of revenue, compared to a net loss of $25.4 million in the third quarter of 2023. Cash was $330.1 million as of September 30, 2024 compared to $362.8 million as of June 30, 2024. 2024 Financial Outlook TransMedics continues to expect revenue for the full year 2024 to be in the range of $425 million to $445 million, which represents 76% to 84% growth compared to the company's prior year revenue. Das klingt ansich ganz gut.

"Gross margin for the third quarter of 2024 was 56%, compared to 61% in the third quarter of 2023."

Umsatz auch ein paar Prozent verfehlt

EPS Miss um 60% 0,12$ statt 0,29$

Findet jemand den Fehler?

https://www.prnewswire.com/news-releases/transmedics-reports-third-quarter-2024-financial-results-302288940.html

Und das zeigt sich 🍀

Top zahlen, Ausblick angehoben. Schmeckt

https://finance.yahoo.com/news/transmedics-tmdx-q2-earnings-revenues-214512785.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAABCmTeUi1PfBK9fGI6U8ogG87y1tWw_xQR3CE_x6OlDFqkpuEhzZMbtbvsfPY_02zAvvOovtIfACFvDOO9ZakCrlnCWjJIK71uo1FtPqXwN2XDUNGjgv13D9Al5ATc9DB55_bbHWTigC9_C6MBJ9vKKATvfeKf7NUpa_l9CY-n-6

https://www.prnewswire.com/news-releases/transmedics-reports-second-quarter-2024-financial-results-302211506.html

Verkauft 75% meiner Position. Über 350% plus. Den Rest lasse ich laufen

Beste aktie

Kiss me where it smells funny!

https://www.prnewswire.com/news-releases/transmedics-reports-first-quarter-2024-financial-results-302132100.html

Geile Aktie, episches Wachstum. Stärker als SaaS/Cloud Player und ohne Wettbewerb! Bin schon fast 300% im Plus

https://seekingalpha.com/news/4071880-transmedics-group-gaap-eps-of-0_12-beats-0_16-revenue-of-81_2m-beats-12_7m • TransMedics Group press release (NASDAQ:TMDX): Q4 GAAP EPS of $0.12 beats by $0.16. • Revenue of $81.2M (+158.6% Y/Y) beats by $12.7M. • The increase was due primarily to the increase in utilization of the OCS through the National OCS Program ("NOP") as well as additional revenue generated by the addition of TransMedics logistics services. • TransMedics expects total revenue for full-year 2024 to be in the range of $360 million to $370 million, which represents 49% to 53% growth compared to the company's prior year revenue.